Genomic variants-driven drug repurposing for tuberculosis by utilizing the established bioinformatic-based approachShort communication Published on 2022-12-012022-10-05 Journal: Biochemistry and Biophysics Reports [Category] 신약개발, [키워드] annotations applied approach bioinformatics biological process CCR5 CD44 cellular component contribute CXCR4 demonstrated deregulation disease disease-associated drug Drug discovery Drug repurposing drug target evaluated Evidence facilitate functional functional annotation Genes genomic genomic variant genomic variants GWAS HLA-B identify implementation in-silico indication involved KEGG Missense mutation molecular overlapped Pathogenesis Pathway analysis provided risk SELP suggested target Treatment Tuberculosis variant [DOI] 10.1016/j.bbrep.2022.101334 [Article Type] Short communication
Molecular evidence for SARS-CoV-2 in samples collected from patients with morbilliform eruptions since late 2019 in Lombardy, northern ItalyArticle Published on 2022-12-012022-11-15 Journal: Environmental research [Category] COVID19(2023년), SARS, 진단, 치료기술, [키워드] anti-SARS-CoV-2 antibody anti-SARS-CoV-2 IgG association B.1 Brazil circulation collected COVID-19 database detectable anti-SARS-CoV-2 antibodies downloaded emergence evaluated Evidence group highlight IgA antibodies IgG and IgM IgM individual Infection investigated Italy Laboratory lombardy measles molecular Mutation oropharyngeal swab outbreak pandemic Patient patients PCR positive positive patient producing Rash reported retrospective RNA SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 RNA SARS-CoV-2. screened sequence sequence information Sequencing Spread strain subjects Surveillance syndrome tested Urine virus Wuhan [DOI] 10.1016/j.envres.2022.113979 PMC 바로가기
Combining intramuscular and intranasal homologous prime-boost with a chimpanzee adenovirus-based COVID-19 vaccine elicits potent humoral and cellular immune responses in mice근육내 및 비강내 상동 프라임-부스트를 침팬지 아데노바이러스 기반 COVID-19 백신과 결합하면 마우스에서 강력한 체액성 및 세포성 면역 반응을 이끌어냅니다.Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 addition Adenovirus adenovirus-based Adenovirus-vectored vaccine Administered antibody titres approach BALB/c mice booster Cellular immune response ChAdTS-S coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic COVID-19 vaccine COVID-19 vaccines cytokine decrease Efficacy elicit elicited evaluated followed by group highest homologous humoral IFN-γ IFN-γ ELISPOT IgA IgG immune immune responses immunogenicity intracellular cytokine staining intramuscular intramuscular vaccination intranasal intranasal. Meso Scale Discovery mice prime immunization priming protocol provide pseudovirus neutralizing antibody respiratory responsible SARS-CoV-2 serotype shown T-cell Response T-cell responses tested titre vaccination Vaccine variants vectored vaccine [DOI] 10.1080/22221751.2022.2097479 PMC 바로가기 [Article Type] Article
Preclinical assessment and randomized Phase I study of CT-P63, a broadly neutralizing antibody targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Article Published on 2022-12-012022-11-15 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 비임상, 진단, 치료기술, 치료제, [키워드] acute respiratory syndrome Beta Blood caused clinically Concentration coronavirus COVID-19 creatine phosphokinase CT-P63 deaths declining Delta demonstrated detectable dose double-blind evaluated groups healthy volunteer Immunity in vitro in vivo Infection Infectious virus lung monoclonal monoclonal antibody morbidity and mortality mutated variant Neutralizing Neutralizing activity neutralizing antibody neutralizing antibody. omicron pandemic parallel-group participant peaked phase Placebo placebo-controlled Preclinical prevalent Prophylactic Randomized reduced respiratory tract Safe SARS-CoV-2 SARS-CoV-2 variant SARS-CoV-2 variants of concern Serious Adverse Events significantly single ascending dose study drug TEAE titre Tolerability Transgenic mouse treated Treatment treatment-emergent adverse event vaccination variants variants of SARS-CoV-2 wild-type [DOI] 10.1080/22221751.2022.2117094 PMC 바로가기
Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIVHIV 보균자에서 비활성화된 SARS-CoV-2 백신의 안전성 및 면역원성Observational Study Published on 2022-12-012022-09-12 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 임상, 진단, [키워드] adverse event age Analysis binding domain booster dose CD4 CD4 count CD4 counts Cell COVID-19 declined Efficacy enrolled evaluated Factor Frequency Gender geometric GMT healthy control healthy controls HIV humoral humoral immune response IgG immune immune response Immunocompromised in both groups inactivated Inactivated vaccine less MBC memory B occurred Patient PLWH predicted prospective observational study reduced remained reported response responses robust Safety Safety. SARS-CoV-2 SARS-CoV-2 vaccine Serious Adverse Event Seven significantly vaccination Viral load with HIV [DOI] 10.1080/22221751.2022.2059401 PMC 바로가기 [Article Type] Observational Study
Probing marine brown macroalgal phlorotannins as antiviral candidate against SARS-CoV-2: molecular docking and dynamics simulation approachArticle Published on 2022-12-012022-11-15 Journal: Molecular diversity [Category] COVID19(2023년), SARS, 치료제, [키워드] 3CLpro antagonist Antiviral antiviral intervention approach AutoDock binding affinities binding affinity candidate Compound compounds COVID-19 COVID-19 therapeutics Cys145 deviation docking Drug discovery drug-likeness Efficacy evaluated GLN189 Glu166 immunostimulatory inhibit interaction site MD simulation molecular molecular docking Molecular docking and dynamics simulation over Phlorotannin polyphenol Probing RdRP reported SARS-CoV-2 SARS-CoV-2 replication SARS-CoV-2. selected target protein target proteins targets therapeutic Thr190 were assessed [DOI] 10.1007/s11030-022-10383-y PMC 바로가기
A case-case study on the effect of primary and booster immunization with China-produced COVID-19 vaccines on prevention of pneumonia and viral load among vaccinated persons infected by Delta and Omicron variantsDelta 및 Omicron 변종에 감염된 백신 접종자의 폐렴 및 바이러스 부하 예방에 대한 중국산 COVID-19 백신의 1차 및 추가 접종 효과에 대한 사례 연구Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, [키워드] administration age analysed association booster booster dose booster immunization calculate case study case-case study COVID-19 COVID-19 outbreak COVID-19 pneumonia COVID-19 vaccine Ct value Ct values Delta determine eligible evaluated immunization Infection infections less Logistic regression no difference no differences Odds ratio Odds ratios omicron pace Pneumonia real-world study. recipient reduced reduction SARS-CoV-2 viral load vaccination Vaccination Status variant Viral load [DOI] 10.1080/22221751.2022.2103455 PMC 바로가기 [Article Type] Article
Humoral responses after inactivated COVID-19 vaccination in individuals with and without prior SARS-CoV-2 infection: A prospective cohort studyArticle Published on 2022-12-012022-11-15 Journal: Journal of medical virology [Category] COVID19(2023년), SARS, 변종, 진단, 치료기술, [키워드] acute respiratory syndrome antibody asymptomatic infections benefit blood sample booster dose Clinical severity collected coronavirus coronavirus disease COVID-19 COVID-19 vaccination detectable dose evaluated Evidence first dose humoral humoral immune response Humoral immunity Humoral response inactivated Inactivated COVID-19 vaccine individual individuals infected individuals Infection median mild cases moderate multicenter NAb titer NAbs naïve individual naïve individuals natural infection Neutralizing Neutralizing activity neutralizing antibody omicron pan-immunoglobulins. participant prospective cohort study Protein receive recovered patient SARS-CoV-2 second dose seroconversion rate severity significantly single dose single vaccine the vaccine U/mL vaccination variant [DOI] 10.1002/jmv.28055 PMC 바로가기
Sputum characteristics of patients with severe COVID-19: report of two cases with immunocytochemical detection of SARS-CoV-2 spike proteinArticle Published on 2022-12-012022-11-15 Journal: Medical molecular morphology [Category] COVID19(2023년), SARS, 치료기술, [키워드] aggregation alveolar Analysis can be used CD68 Cell cells characteristics of patient chromatin COVID-19 cytological cytoplasmic definitive diagnosis double infection epithelial evaluated exclusion expression Herpe herpes simplex herpes simplex virus immunocytochemistry Inclusion infected cell Infection intranuclear multinuclear nuclear nuclei Patient performed pneumocyte positive protein A SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 spike SARS-CoV-2 spike protein severe COVID-19 simplex specimen sputum Sputum sample Sputum. staining These cells Treatment viral infection virus [DOI] 10.1007/s00795-022-00326-9 PMC 바로가기
Heterologous boosting with third dose of coronavirus disease recombinant subunit vaccine increases neutralizing antibodies and T cell immunity against different severe acute respiratory syndrome coronavirus 2 variants코로나바이러스 질병 재조합 소단위 백신의 세 번째 용량으로 이종 부스팅은 다양한 중증 급성 호흡기 증후군 코로나바이러스 2 변이체에 대한 중화 항체 및 T 세포 면역을 증가시킵니다Article Published on 2022-12-012022-09-11 Journal: Emerging Microbes & Infections [Category] COVID19(2023년), SARS, 변종, 진단, [키워드] acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus 2 Analysis Anti-RBD IgG anti-S booster vaccination CD4+ T cell components composite pattern coronavirus coronavirus disease COVID-19 COVID-19 vaccinations COVID-19 vaccine dose effective epitope Epitopes evaluated Evidence help Heterologous heterologous boosting homologous Humoral immunity Immune escape Immunity immunization strategy immunological in some inactivated Inactivated vaccine increase magnitude NAb NAbs natural infection Neutralizing Neutralizing antibodies neutralizing antibody neutralizing capacity omicron pandemic prime-boost strategy produced RBD IgG respiratory subunit Subunit vaccine Subunit vaccine. T cell T cell response T cells titre vaccination Vaccination strategies Vaccination strategy Vaccine Vaccine-induced immunity variant variants of concern waned [DOI] 10.1080/22221751.2022.2048969 PMC 바로가기 [Article Type] Article